Crea F - Search Results

1

Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.

Ricciardi S, Mey V, Nannizzi S, Pasqualetti G, Crea F, Del Tacca M, Danesi R. Ricciardi S, et al. Among authors: crea f. Chemotherapy. 2010;56(4):303-12. doi: 10.1159/000320031. Epub 2010 Aug 13. Chemotherapy. 2010. PMID: 20714148

2

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.

Crea F, Giovannetti E, Zinzani PL, Danesi R. Crea F, et al. Crit Rev Oncol Hematol. 2009 Oct;72(1):21-44. doi: 10.1016/j.critrevonc.2008.10.014. Epub 2008 Dec 25. Crit Rev Oncol Hematol. 2009. PMID: 19111474 Review.

3

Pharmacogenomics in non-small-cell lung cancer chemotherapy.

Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M, Rosell R. Danesi R, et al. Among authors: crea f. Adv Drug Deliv Rev. 2009 May 20;61(5):408-17. doi: 10.1016/j.addr.2009.03.001. Epub 2009 Mar 16. Adv Drug Deliv Rev. 2009. PMID: 19292993 Review.

4

Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.

Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, Gallegos Ruiz MI, Ricciardi S, Del Tacca M, Peters GJ, Danesi R. Crea F, et al. Mol Cancer Ther. 2009 Jul;8(7):1964-73. doi: 10.1158/1535-7163.MCT-09-0027. Epub 2009 Jun 16. Mol Cancer Ther. 2009. PMID: 19531575

5

BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.

Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R, Farrar WL. Crea F, et al. Int J Cancer. 2011 Apr 15;128(8):1946-54. doi: 10.1002/ijc.25522. Int J Cancer. 2011. PMID: 20568112 Free PMC article.

6

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R. Pastina I, et al. Among authors: crea f. BMC Cancer. 2010 Sep 27;10:511. doi: 10.1186/1471-2407-10-511. BMC Cancer. 2010. PMID: 20875115 Free PMC article.

7

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.

Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R, Farrar WL. Crea F, et al. Mol Cancer. 2011 Apr 18;10:40. doi: 10.1186/1476-4598-10-40. Mol Cancer. 2011. PMID: 21501485 Free PMC article.

8

Pharmacogenomics and cancer stem cells: a changing landscape?

Crea F, Duhagon MA, Farrar WL, Danesi R. Crea F, et al. Trends Pharmacol Sci. 2011 Aug;32(8):487-94. doi: 10.1016/j.tips.2011.03.010. Epub 2011 Apr 27. Trends Pharmacol Sci. 2011. PMID: 21529973 Free PMC article. Review.

9

Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?

Crea F, Fornaro L, Masi G, Falcone A, Danesi R, Farrar W. Crea F, et al. J Clin Oncol. 2011 Sep 1;29(25):3487-8; author reply 3488-90. doi: 10.1200/JCO.2011.37.0122. Epub 2011 Jul 25. J Clin Oncol. 2011. PMID: 21788560 No abstract available.

10

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.

Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, Salvatore L, Cremolini C, Schirripa M, Graziano F, Ronzoni M, Ricci V, Farrar WL, Falcone A, Danesi R. Crea F, et al. Ann Oncol. 2012 May;23(5):1207-1213. doi: 10.1093/annonc/mdr387. Epub 2011 Sep 16. Ann Oncol. 2012. PMID: 21926398 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,698 results

Search Page

Filters